Independent · Updated 11 Nov 2026
Longevity Drug Index
10 candidates for slowing aging, scored on animal lifespan studies and human aging data.
Rapamycin
Animal lifespan
Human aging data
Up to 26% longer median life in mice →
| Rank | Drug | Lifespan in healthy animals | Human aging data | Verdict |
|---|---|---|---|---|
| 1 | Rapamycin | Strongest and most replicated; multiple labs, both sexes, many species, works when started late | Small trials in healthy older adults: safety and immune benefits | Still the best-proven in animals |
| 2 | GLP-1 drugs semaglutide, tirzepatide | One strong Nature study (2026): late-life semaglutide extended median lifespan in female mice by about 12% | Placebo-controlled aging-clock data from Novo (2 to 3 years younger) and early single-arm data from Lilly, plus a small randomised trial; all in overweight, diabetic or HIV patients | Fastest-rising candidate; healthy-human trial under way |
| 3 | Acarbose | Robust in the NIA program, mainly males | None | Strong but neglected |
| 4 | SGLT2 inhibitors canagliflozin | Extended male mouse lifespan in the NIA program | None in healthy people | Promising |
| 5 | Captopril | Modest extension in the NIA program | None | Weak signal |
| 6 | Senolytics | Positive in mice, mostly aged or damaged animals | Small, mixed | Unproven |
| 7 | Metformin | Failed in the NIA program | Small trials; may blunt exercise gains | Disappointing |
| 8 | Statins | Weak | Little benefit in truly low-risk people | Only with real risk |
| 9 | Rilmenidine | Worms only | None | Too early |
| 10 | Telmisartan, perindopril, bisphosphonates | Little or none | None | Speculative |
Why the top three could help
Rapamycin
Turns down the cell’s growth switch
Rapamycin blocks mTOR, a sensor that tells cells to grow when nutrients are plentiful. Dialling it down mimics some effects of eating less: cells clear out and recycle damaged parts (autophagy), and the immune system ages more slowly. In mice it extends lifespan in both sexes, even when started in old age.
Read the full profile →GLP-1 drugs
Treat the diseases that drive aging
Semaglutide and tirzepatide lower weight, blood sugar and inflammation, and large trials show fewer heart attacks, strokes and cases of kidney decline. Some benefits appear before much weight is lost, pointing to direct effects on blood vessels, the brain and the immune system. In aging-clock studies, treated patients looked 2 to 3 years biologically younger than on placebo.
Read the full profile →Acarbose
Flattens blood sugar spikes
Acarbose slows the digestion of starch and sugar, so blood sugar rises less after meals. Repeated spikes damage proteins and blood vessels over time. The undigested carbohydrate also feeds gut bacteria that make protective short-chain fatty acids. It is an old, cheap diabetes pill that extended lifespan in mice, most clearly in males.
Read the full profile →How to read this index
The ranking puts most weight on lifespan studies in healthy animals, especially results replicated across labs, both sexes and the NIA Interventions Testing Program. Human data is mostly limited to small trials or aging biomarkers in people who are already ill, so no drug here has been shown to slow aging in healthy humans.
Not a treatment guide
None of these drugs is approved to slow aging. Several carry real side effects, and taking them off-label without a clinical reason is not recommended. Speak to a licensed clinician before starting or changing any medication.
Last reviewed 11 November 2026. General information, not medical advice.